***To the Editor:*** I have read with great interest the recent article by Vijayvargiya et al,[@bib1] which was published in *Mayo Clinic Proceedings.* Many of the deaths caused by severe acute respiratory syndrome coronavirus 2 are in patients older than 55 years of age, who develop acute respiratory distress syndrome (ARDS).

At the histological level, ARDS is characterized by an intense inflammatory response occurring in the lungs of patients.[@bib2] Human aging is associated with an up-regulated inflammatory response.[@bib3]

Inflammation is involved in the mechanisms underlying the pathogenesis of several age-associated diseases such as cardiovascular disease, type 2 diabetes, Alzheimer disease, Parkinson disease, rheumatoid arthritis, and osteoporosis.

Elderly individuals have lost the ability to control and contain inflammatory processes to the same degree of which younger individuals are capable. The innate immune system plays a central role in inflammation and is also key in its ability to slow down and arrest inflammatory processes. Interleukin-10 (IL-10) and C1-esterase inhibitors are 2 molecules that help contain and slow down inflammatory processes, whereas IL-6 promotes and intensifies inflammation (though it also has some anti-inflammatory properties in muscle cells). Given the up-regulation of inflammatory processes with aging, it is not surprising that ARDS is usually more severe and more lethal in the elderly. COVID-19 triggers a "cytokine storm" that involves multiple organ systems. In the kidneys, it leads to renal insufficiency and failure, and in the vascular system, it causes a vasculitis, which is at first visible as pernio or chilblain lesions in the toes ("coronavirus toes") but that can involve also large blood vessels. The central nervous system is not spared, resulting in headaches, altered mental status, confusion, or inability to arouse, as well as the loss of the sense of smell, which is reportedly one of the early symptoms of the disease. Thirty-six percent of patients had some type of neurological symptom. On the mild end of the spectrum, people commonly had the loss of taste and smell. Headache was reported in 13% of patients; dizziness was observed in about 17%; and muscle inflammation and nerve pain occurred in about 19%. Autopsy reports have revealed brain tissue edema and partial neuronal degeneration in deceased patients. To effectively treat the cytokine storm, tocilizumab (Actemra) has been used to block the proinflammatory action of IL-6 and seems to have been helpful in anecdotal cases (3 patients treated in Italy). C1-esterase inhibitor (Berinert, Cinryze, and Ruconest) could also be tested to see whether it is capable of slowing down the inflammatory response. But these are expensive medications and difficult to produce rapidly in quantities. Using them to treat tens of thousands of patients may prove impossible because of cost and logistics. Interleukin-10 is another anti-inflammatory molecule that could be tested, and it could be administered via a gene therapy approach using naked plasmid DNA vectors[@bib4] engineered to produce IL-10 inside the recipient cells, thus reducing cost and simplifying production. It would be more cost-effective for treating many thousands of patients.

COVID-19 infection involves multiple organs and systems, with symptoms developing rapidly over 2 to 14 days. Most infections however produce mild or minimal symptoms, and up to 80% of persons infected may have mild disease or even be asymptomatic. Reports from Italy indicate that some individuals continue to have positive nasal swab tests for COVID-19 for at least 50 days after their initial positive test and after having apparently recovered from the illness. There is one case of a person who has had positive nasal swab test results for 57 days. This raises the possibility that some individuals, after recovering from their illness, may become asymptomatic carriers of the virus for extended periods of time, further complicating efforts to contain the pandemic and requiring that patients be tested after their recovery to make sure they clear the virus. This means that antiviral therapies and vaccines will be needed. Countries need to invest in technologies such as DNA vaccines[@bib5] and antiviral gene therapy strategies such as RNA Interference (RNAi) technology, which is an ideal tool to inhibit viral replication in host cells as small interfering RNA can interact with certain viral genes and silence their expression.[@bib6] DNA-based therapeutics can be developed immediately after a virus DNA sequence becomes known. Modular plasmid vectors could be created that allow to switch one viral sequence for another and produce a new vaccine with minimal manipulation. The same applies to RNAi vectors. These strategies are also likely to be much more cost-effective than other methods, a consideration that becomes important as the population needing treatment expands.

We need to develop detailed protocols now on how to quickly produce vaccines and antiviral therapies that can be adapted to future viral pandemics. We also need to develop protocols for the most effective containment and mitigation strategies so that they can be implemented without hesitation in future emergencies.
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